Kampo medicines for gastrointestinal tract disorders: A review of basic science and clinical evidence and their future application

Journal of Gastroenterology

Volumn 48, Issue 4, 2013, Pages 452-462

  Tominaga, Kazunari ^a   Arakawa, Tetsuo ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti inflammation; Functional dyspepsia (FD); Functional gastrointestinal disorders (FGIDs); Gastroesophageal reflux disease (GERD); Gastrointestinal motility; Irritable bowel syndrome (IBS); Post operative ileus; Traditional herbal medications

Indexed keywords

1 METHYL 2 [7 TRIDECENYL] 4 (1H) QUINOLONE; 1 METHYL 2 [8 TRIDECENYL] 4 (1H) QUINOLONE; AMOXICILLIN; DAIKENCHUTO; DOMPERIDONE; GOSYUYUTO; HANGESHASHINTO; KAMPO; NALOXONE; OMEPRAZOLE; QUINOLONE DERIVATIVE; RIKKUNSHITO; UNCLASSIFIED DRUG; XIAO CHAI HU TANG; HERBACEOUS AGENT;

ABSENCE OF SIDE EFFECTS; CHRONIC GASTRITIS; COLITIS; CONSTIPATION; DYSPEPSIA; ERADICATION THERAPY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HELICOBACTER INFECTION; HUMAN; ILEUS; INDIGESTION; IRRITABLE COLON; JAPAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; STOMACH INJURY; CHINESE MEDICINE; DRUG EFFECT; EVIDENCE BASED MEDICINE; GASTRITIS; GASTROINTESTINAL MOTILITY; METHODOLOGY;

DRUGS, CHINESE HERBAL; DYSPEPSIA; EVIDENCE-BASED MEDICINE; GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MOTILITY; HUMANS; MEDICINE, KAMPO;

EID: 84886562612     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-013-0788-z     Document Type: Review

References (121)

1. Furukawa N, Iwakiri R, Koyama T, Okamoto K, Yoshida T, Kashiwagi Y, et al. Proportion of reflux esophagitis in 6010 Japanese adults: prospective evaluation by endoscopy. J Gastroenterol. 1999;34: 441-4.
2. Shimazu T, Matsui T, Furukawa K, Oshige K, Mitsuyasu T, Kiyomizu A, et al. A prospective study of the prevalence of gastroesophageal reflux disease and confounding factors. J Gastroenterol. 2005;40: 866-72.
3. Mishima I, Adachi K, Arima N, Amano K, Takashima T, Moritani M, et al. Prevalence of endoscopically negative and positive gastroesophageal reflux disease in the Japanese. Scand J Gastroenterol. 2005;40: 1005-9.
4. Fujiwara Y, Arakawa T. Epidemiology and clinical characteristics of GERD in the Japanese population. J Gastroenterol. 2009;44: 518-34.
5. Vakil N, van Zanten SV, Kahrialis P, Dent J, Jones R. The Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101: 1900-20.
6. Dodds WJ, Hogan WJ, Helm JF, Dent J. Pathogenesis of reflux esophagitis. Gastroenterology. 1981;81: 376-94.
7. Coté GA, Howden CW. Potential adverse effects of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10: 208-14.
8. Hattori T, Fujitsuka N, Asakawa A, Inui A. A strategy using Rikkunshito (Liu-Jun-Zi-Tang), a Japanese traditional medicine, to treat gastrointestinal disease. In: Basics of evidencesbased herbal medicine. Kerala: Research Signpost Press; 2010. p. 149-60.
9. Hayakawa T, Arakawa T, Kase Y, Akiyama S, Ishige A, Takeda S, et al. Liu-Jun-Zi-Tang, a kampo medicine, promotes adaptive relaxation in isolated guinea pig stomachs. Drugs Exp Clin Res. 1999;25: 211-8.
10. Kido T, Nakai Y, Kase Y, Sakakibara I, Nomura M, Takeda S, et al. Effects of rikkunshi-to, a traditional Japanese medicine, on the delay of gastric emptying induced by N(G)-nitro-L-arginine. J Pharmacol Sci. 2005;98: 161-7.
11. Tominaga K, Kido T, Ochi M, Sadakane C, Mase A, Okazaki H, et al. The traditional Japanese medicine rikkunshito promotes gastric emptying via the antagonistic action of the 5-HT3 receptor pathway in rats. Evid Based Complement Alternat Med. 2009;1-8. doi:10.1093/ecam/nep173.
12. Takeda H, Sadakane C, Hattori T, Katsurada T, Ohkawara T, Nagai K, et al. Rikkunshito, an herbal medicine, suppresses cisplatin-induced anorexia in rats via 5-HT2 receptor antagonism. Gastroenterology. 2008;134: 2004-13.
13. Yakabi K, Sadakane C, Noguchi M, Ohno S, Ro S, Chinen K, et al. Reduced ghrelin secretion in the hypothalamus of rats due to cisplatin-induced anorexia. Endocrinology. 2010;151: 3773-82.
14. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402: 656-60.
15. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, et al. A role for ghrelin in the central regulation of feeding. Nature. 2001;409: 194-8.
16. Fujino K, Inui A, Asakawa A, Kihara N, Fujimura M, Fujimiya M. Ghrelin induces fasted motor activity of the gastrointestinal tract in conscious fed rats. J Physiol. 2003;550: 227-40.
17. Inui A, Asakawa A, Bowers CY, Mantovani G, Laviano A, Meguid MM, et al. Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ. FASEB J. 2004;18: 439-56.
18. Masuda Y, Tanaka T, Inomata N, Ohnuma N, Tanaka S, Itoh Z, et al. Ghrelin stimulates gastric acid secretion and motility in rats. Biochem Biophys Res Commun. 2000;276: 905-8.
19. Nahata M, Muto S, Oridate N, Ohnishi S, Nakagawa K, Sadakane C, et al. Impaired ghrelin signaling is associated with gastrointestinal dysmotility in rats with gastroesophageal reflux disease. Am J Physiol Gastrointest Liver Physiol. 2012;303: G42-53.
20. Kawahara H, Kubota A, Hasegawa T, Okuyama H, Ueno T, Ida S, et al. Effects of rikkunshito on the clinical symptoms and esophageal acid exposure in children with symptomatic gastroesophageal reflux. Pediatr Surg Int. 2007;23: 1001-5.
21. Hiyama T, Yoshihara M, Tanaka S, Haruma K, Chayama K. Strategy for treatment of nonerosive reflux disease in Asia. World J Gastroenterol. 2008;14: 3123-8.
22. Tominaga K, Iwakiri R, Fujimoto K, Fujiwara Y, Tanaka M, Shimoyama Y, et al. Rikkunshito improves symptoms in PPIrefractory GERD patients: a prospective, randomized, multicenter trial in Japan. J Gastroenterol. 2012;47(3): 284-92.
23. Miwa H, Koseki J, Oshima T, Kondo T, Tomita T, Watari J, et al. Rikkunshito, a traditional Japanese medicine, may relieve abdominal symptoms in rats with experimental esophagitis by improving the barrier function of epithelial cells in esophageal mucosa. J Gastroenterol. 2010;45: 478-87.
24. Araki Y, Mukaisho KI, Fujiyama Y, Hattori T, Sugihara H. The herbal medicine rikkunshito exhibits strong and differential adsorption properties for bile salts. Exp Ther Med. 2012;3(4): 645-9.
25. Kinoshita Y, Hongo M. Japan TWICE Study Group. Efficacy of twice-daily rabeprazole for reflux esophagitis patients refractory to standard once-daily administration of PPI: the Japan-based TWICE study. Am J Gastroenterol. 2012;107(4): 522-30.
26. Takeuchi K. Pathogenesis of NSAID-induced gastric damage: importance of cyclooxygenase inhibition and gastric hypermotility. World J Gastroenterol. 2012;18(18): 2147-60.
27. Watanabe T, Higuchi K, Tominaga K, Fujiwara Y, Arakawa T. Cytoprotective effect of rabeprazole against ethanol-induced gastric mucosal damage: possible involvement of nitric oxide. Drugs Exp Clin Res. 2000;26(2): 41-5.
28. Hamaguchi M, Watanabe T, Higuchi K, Tominaga K, Fujiwara Y, Arakawa T. Mechanisms and roles of neutrophil infiltration in stress-induced gastric injury in rats. Dig Dis Sci. 2001; 46(12): 2708-15.
29. Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci. 1998;43(9 Suppl):5S-13S.
30. Yanaka A, Zhang S, Sato D, Tauchi M, Suzuki H, Shibahara T, et al. Geranylgeranylacetone protects the human gastric mucosa from diclofenac-induced injury via induction of heat shock protein 70. Digestion. 2007;75(2-3): 148-55.
31. Kase Y, Yuzurihara M, Iizuka S, Ishige A, Komatsu Y. The effects of hange-shashin-to on gastric function in comparison with sho-saiko-to. Biol Pharm Bull. 1997;20(11): 1155-9.
32. Goso Y, Ogata Y, Ishihara K, Hotta K. Effects of traditional herbal medicine on gastric mucin against ethanol-induced gastric injury in rats. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1996;113(1): 17-21.
33. Arakawa T, Higuchi K, Fujiwara Y, Watanabe T, Tominaga K, Hayakawa T, et al. Gastroprotection by Liu-Jun-Zi-Tang (TJ- 43): possible mediation of nitric oxide but not prostaglandins or sulfhydryls. Drugs Exp Clin Res. 1999;25(5): 207-10.
34. Ishii E. Genus Helicobacter pylori in stomach and antibacterial activity of natural materials against Helicobacter pylori. Gastroenterol Semin. 1997;68: 143-52.
35. Higuchi K, Arakawa T, Ando K, Fujiwara Y, Uchida T, Kuroki T. Eradication of Helicobacter pylori with a Chinese herbal medicine without emergence of resistant colonies. Am J Gastroenterol. 1999;94: 1419-20.
36. Hamasaki N, Ishii E, Tominaga K, Tezuka Y, Nagaoka T, Kadota S, et al. Highly selective antibacterial activity of novel alkyl quinolone alkaloids from a Chinese herbal medicine, Gosyuyu (Wu-Chu-Yu), against Helicobacter pylori in vitro. Microbiol Immunol. 2000;44(1): 9-15.
37. Tominaga K, Higuchi K, Hamasaki N, Hamaguchi M, Takashima T, Tanigawa T, et al. In vivo action of novel alkyl methyl quinolone alkaloids against Helicobacter pylori. J Antimicrob Chemother. 2002;50(4): 547-52.
38. Halder SL, Locke GR 3rd, Tally NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Impact of functional gastrointestinal disorders on health-related quality of life: a population-based case control study. Aliment Pharmacol Ther. 2004;19: 233-42.
39. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006;130: 1377-90.
40. Tominaga K, Higuchi K, Ochi M, Kadouchi K, Kawamura E, Tanigawa T, et al. Concurrent assessment of reservoir and emptying of the stomach for dyspepsia patients. Hepatogastroenterology. 2008;55: 744-9.
41. el-Omar E, Penmann I, Ardill JE, McColl KE. A substantial proportion of non-ulcer dyspepsia patients have the same abnormality of acid secretion as duodenal ulcer patients. Gut. 1995;36: 534-8.
42. Salet GA, Samsom M, Roelofs JM, van Berge Henegouwen GP, Smout AJ, Akkermans LM. Responses to gastric distension in functional dyspepsia. Gut. 1998;42: 823-9.
43. Holtmann G, Gschossmann J, Holtmann M, Holtmann M, Talley NJ. H. pylori and functional dyspepsia: increased serum antibodies as an independent risk factor? Dig Dis Sci. 2001;46: 1550-7.
44. Tominaga K, Higuchi K, Iketani T, Ochi M, Kadouchi K, Tanigawa T, et al. Comparison of gastrointestinal symptoms and psychological factors of functional dyspepsia to peptic ulcer or panic disorder patients. Inflammopharmacology. 2007;15: 84-9.
45. Ochi M, Tominaga K, Iketani T, Kadouchi K, Tanigawa T, Shiba M, et al. Perfectionism underlying psychological background correlated with the symptoms of functional dyspepsia. J Gastroenterol. 2008;43: 699-704.
46. Park DI, Rhee PL, Kim YH, Sung IK, Son HJ, Kim JJ, et al. Role of autonomic dysfunction in patients in patients with functional dyspepsia. Dig Liver Dis. 2001;33: 464-71.
47. Savoye G, Bouin M, Denis P, Ducrotte P. Delayed postprandial fundic relaxation: a new abnormal finding in functional dyspepsia. Scand J Gastroenterol. 2005;40(3): 354-5.
48. Desai KM, Zembowicz A, Sessa WC, Vane Jr. Nitroxergic nerves mediate vagally induced relaxation in the isolated stomach of the guinea pig. Proc Natl Acad Sci USA. 1991; 88(24): 11490-4.
49. Uno H, Arakawa T, Fukuda T, Higuchi K, Kobayashi K. Involvement of capsaicin-sensitive sensory nerves in gastric adaptive relaxation in isolated guinea-pig stomachs. Digestion. 1997;58(3): 232-9.
50. Bredenoord AJ, Chial HJ, Camilleri M, Mullan BP, Murray JA. Gastric accommodation and emptying in evaluation of patients with upper gastrointestinal symptoms. Clin Gastroenterol Hepatol. 2003;1(4): 264-72.
51. Kito Y, Suzuki H. Properties of Rikkunshi-to (TJ-43)-induced relaxation of rat gastric fundus smooth muscles. Am J Physiol Gastrointest Liver Physiol. 2010;298(5):G755-63.
52. Tatsuta M, Iishi H. Effect of treatment with Lui-Jun-Zi-Tang (TJ-43) on gastric emptying and gastrointestinal symptoms in dyspeptic patients. Aliment Pharmacol Ther. 1993;7: 459-62.
53. Kusunoki H, Haruma K, Hata J, Ishii M, Kamada T, Yamashita N, et al. Efficacy of Rikkunshito, a traditional Japanese medicine (Kampo), in treating functional dyspepsia. Intern Med. 2010;49(20): 2195-202.
54. Shiratori M, Shoji T, Kanazawa M, Hongo M, Fukudo S. Effect of rikkunshito on gastric sensorimotor function under distention. Neurogastroenterol Motil. 2011;23(4): 323-9.
55. Sato Y, Katagiri F, Itoh H, Takeyama M. Effects of some kampo medicines on plasma levels of neuropeptide Y under venipuncture stress. Biol Pharm Bull. 2005;28(9): 1757-61.
56. Fujitsuka N, Asakawa A, Uezono Y, Minami K, Ymaguchi T, Niijima A, et al. Potentiation of ghrelin signaling attenuates cancer anorexia-cachexia and prolongs survival. Transl Psychiatry. 2011;26:e23.
57. Tominaga K, Higuchi K, Kadouchi K, Sasaki E, Shiba M, Watanabe T, et al. Disorder of circadian rhythm of autonomic nervous system activity and its correlation with abdominal symptoms in functional dyspepsia. Gastroenterology. 2003; 124(Supplement 1):A225.
58. Arai M, Matsumura T, Tsuchiya N, Sadakane C, Inami R, Suzuki T, et al. Rikkunshito improves the symptoms in patients with functional dyspepsia, accompanied by an increase in the level of plasma ghrelin. Hepatogastroenterology. 2012;59(113): 62-6.
59. Kawahara H, Mitani Y, Nomura M, Nose K, Yoneda A, Hasegawa T, et al. Impact of rikkunshito, an herbal medicine, on delayed gastric emptying in profoundly handicapped patients. Pediatr Surg Int. 2009;25(11): 987-90.
60. Yagi M, Homma S, Kubota M, Iinuma Y, Kanada S, Kinoshita Y, et al. The herbal medicine Rikkunshi-to stimulates and coordinates the gastric myoelectric activity in post-operative dyspeptic children after gastrointestinal surgery. Pediatr Surg Int. 2004;19(12): 760-5.
61. Oikawa T, Ito G, Hoshino T, Koyama H, Hanawa T. Hangekobokuto (Banxia-houpo-tang), a kampo medicine that treats functional dyspepsia. Evid Based Complement Alternat Med. 2009;6(3): 375-8.
62. Nakamura T, Sakai A, Isogami I, Noda K, Ueno K, Yano S. Abatement of morphine-induced slowing in gastrointestinal transit by Dai-kenchu-to, a traditional Japanese herbal medicine. Jpn J Pharmacol. 2002;88(2): 217-21.
63. Satoh K, Kase Y, Yuzurihara M, Mizoguchi K, Kurauchi K, Ishige A. Effect of Dai-kenchu-to (Da-Jian-Zhong-Tang) on the delayed intestinal propulsion induced by chlorpromazine in mice. J Ethnopharmacol. 2003;86(1): 37-44.
64. Hayakawa T, Kase Y, Saito K, Hashimoto K, Ishige A, Komatsu Y, et al. Effects of Dai-kenchu-to on intestinal obstruction following laparotomy. J Smooth Muscle Res. 1999;35(2): 47-54.
65. Fukuda H, Chen C, Mantyh C, Ludwig K, Pappas TN, Takahashi T. The herbal medicine, Dai-Kenchu-to, accelerates delayed gastrointestinal transit after the operation in rats. J Surg Res. 2006;131(2): 290-5.
66. Tokita Y, Satoh K, Sakaguchi M, Endoh Y, Mori I, Yuzurihara M, et al. The preventive effect of Daikenchuto on postoperative adhesion-induced intestinal obstruction in rats. Inflammopharmacology. 2007;15(2): 65-6.
67. Satoh K, Hayakawa T, Kase Y, Ishige A, Sasaki H, Nishikawa S, et al. Mechanisms for contractile effect of Dai-kenchu-to in isolated guinea pig ileum. Dig Dis Sci. 2001;46(2): 250-6.
68. Satoh K, Kase Y, Hayakawa T, Murata P, Ishige A, Sasaki H. Dai-kenchu-to enhances accelerated small intestinal movement. Biol Pharm Bull. 2001;24(10): 1122-6.
69. Hayakawa T, Kase Y, Saito K, Hashimoto K, Ishige A, Komatsu Y, et al. Pharmacological studies of the effect of Dai-kenchu-to on spontaneous contraction of isolated rabbit jejunum. J Smooth Muscle Res. 1999;35(2): 55-62.
70. Shibata C, Sasaki I, Naito H, Ueno T, Matsuno S. The herbal medicine Dai-Kenchu-Tou stimulates upper gut motility through cholinergic and 5-hydroxytryptamine 3 receptors in conscious dogs. Surgery. 1999;126(5): 918-24.
71. Jin XL, Shibata C, Naito H, Ueno T, Funayama Y, Fukushima K, et al. Intraduodenal and intrajejunal administration of the herbal medicine, dai-kenchu-tou, stimulates small intestinal motility via cholinergic receptors in conscious dogs. Dig Dis Sci. 2001;46(6): 1171-6.
72. Kito Y, Suzuki H. Effects of Dai-kenchu-to on spontaneous activity in the mouse small intestine. J Smooth Muscle Res. 2006;42(6): 189-201.
73. Tokita Y, Yamamoto M, Satoh K, Nishiyama M, Iizuka S, Imamura S, et al. Possible involvement of the transient receptor potential vanilloid type 1 channel in postoperative adhesive obstruction and its prevention by a kampo (traditional Japanese) medicine, daikenchuto. J Pharmacol Sci. 2011;115(1): 75-83.
74. Chikakiyo M, Shimada M, Nakao T, Higashijima J, Yoshikawa K, Nishioka M, et al. Kampo medicine "Dai-kenchu-to" prevents CPT-11-induced small-intestinal injury in rats. Surg Today. 2012;42(1): 60-7.
75. Yoshikawa K, Kurita N, Higashijima J, Miyatani T, Miyamoto H, Nishioka M, et al. Kampo medicine "Dai-kenchu-to" prevents bacterial translocation in rats. Dig Dis Sci. 2008;53(7): 1824-31.
76. Satoh K, Hashimoto K, Hayakawa T, Ishige A, Kaneko M, Ogihara S, et al. Mechanism of atropine-resistant contraction induced by Dai-kenchu-to in guinea pig ileum. Jpn J Pharmacol. 2001;86(1): 32-7.
77. Manabe N, Camilleri M, Rao A, Wong BS, Burton D, Busciglio I, et al. Effect of daikenchuto (TU-100) on gastrointestinal and colonic transit in humans. Am J Physiol Gastrointest Liver Physiol. 2010;298(6):G970-5.
78. Sato Y, Inoue S, Katagiri F, Itoh H, Takeyama M. Effects of pirenzepine on Dai-kenchu-to-induced elevation of the plasma neuropeptide levels in humans. Biol Pharm Bull. 2006;29(1): 166-71.
79. Endo S, Nishida T, Ishikawa K, Nakajima K, Hasegawa J, Kitagawa T, et al. Dai-kenchu-to, a Chinese herbal medicine, improves stasis of patients with total gastrectomy and jejunal pouch interposition. Am J Surg. 2006;192(1): 9-13.
80. Itoh T, Yamakawa J, Mai M, Yamaguchi N, Kanda T. The effect of the herbal medicine dai-kenchu-to on post-operative ileus. J Int Med Res. 2002;30(4): 428-32.
81. Takeda T, Kamiura S, Kimura T. Effectiveness of the herbal medicine daikenchuto for radiation-induced enteritis. J Altern Complement Med. 2008;14(6): 753-5.
82. Ogasawara T, Morine Y, Ikemoto T, Imura S, Fujii M, Soejima Y, et al. Influence of Dai-kenchu-to (DKT) on human portal blood flow. Hepatogastroenterology. 2008;55(82-83): 574-7.
83. Takayama S, Seki T, Watanabe M, Monma Y, Sugita N, Konno S, et al. The herbal medicine Daikenchuto increases blood flow in the superior mesenteric artery. Tohoku J Exp Med. 2009;219(4): 319-30.
84. Murata P, Kase Y, Ishige A, Sasaki H, Kurosawa S, Nakamura T. The herbal medicine Dai-kenchu-to and one of its active components [6]-shogaol increase intestinal blood flow in rats. Life Sci. 2002;70(17): 2061-70.
85. Kawasaki N, Nakada K, Nakayoshi T, Furukawa Y, Suzuki Y, Hanyu N, Yanaga K. Effect of Dai-kenchu-to on gastrointestinal motility based on differences in the site and timing of administration. Dig Dis Sci. 2007;52(10): 2684-94.
86. Wood MJ, Hyman NH, Mawe GM. The effects of daikenchuto (DKT) on propulsive motility in the colon. J Surg Res. 2010;164(1): 84-90.
87. Nagano T, Itoh H, Takeyama M. Effect of Dai-kenchu-to on levels of 3 brain-gut peptides (motilin, gastrin and somatostatin) in human plasma. Biol Pharm Bull. 1999;22(10): 1131-3.
88. Nagano T, Itoh H, Takeyama M. Effects of Dai-kenchu-to on levels of 5-hydroxytryptamine (serotonin) and vasoactive intestinal peptides in human plasma. Biol Pharm Bull. 2000;23(3): 352-3.
89. Kono T, Koseki T, Chiba S, Ebisawa Y, Chisato N, Iwamoto J, et al. Colonic vascular conductance increased by Daikenchuto via calcitonin gene-related peptide and receptor-activity modifying protein 1. J Surg Res. 2008;150(1): 78-84.
90. Sato Y, Katagiri F, Inoue S, Itoh H, Takeyama M. Dai-kenchuto raises levels of calcitonin gene-related peptide and substance P in human plasma. Biol Pharm Bull. 2004;27(11): 1875-7.
91. Kawahara H, Yanaga K. The herbal medicine Dai-Kenchu-To directly stimulatescolonic motility. Surg Today. 2009;39(2): 175-7.
92. Kaiho T, Tanaka T, Tsuchiya S, Yanagisawa S, Takeuchi O, Miura M, et al. Effect of the herbal medicine Dai-kenchu-to for serum ammonia in hepatectomized patients. Hepatogastroenterology. 2005;52(61): 161-5.
93. Suehiro T, Matsumata T, Shikada Y, Sugimachi K. The effect of the herbal medicines dai-kenchu-to and keishi-bukuryo-gan on bowel movement after colorectal surgery. Hepatogastroenterology. 2005;52(61): 97-100.
94. Ohya T, Usui Y, Arii S, Iwai T, Susumu T. Effect of dai-kenchuto on obstructive bowel disease in children. Am J Chin Med. 2003;31(1): 129-35.
95. Iwai N, Kume Y, Kimura O, Ono S, Aoi S, Tsuda T. Effects of herbal medicine Dai-Kenchu-to on anorectal function in children with severe constipation. Eur J Pediatr Surg. 2007; 17(2): 115-8.
96. Takagi A, Yagi M, Tanaka Y, Asagiri K, Asakawa T, Tanaka H, et al. The herbal medicine daikenchuto ameliorates an impaired anorectal motor activity in postoperative pediatric patients with an anorectal malformation-a pilot study. Int Surg. 2010;95(4): 350-5.
97. Sakakibara R, Odaka T, Lui Z, Uchiyama T, Yamaguchi K, Yamaguchi T, et al. Dietary herb extract dai-kenchu-to ameliorates constipation in parkinsonian patients (Parkinson's disease and multiple system atrophy). Mov Disord. 2005;20(2): 261-2.
98. Kono T, Omiya Y, Hira Y, Kaneko A, Chiba S, Suzuki T, et al. Daikenchuto (TU-100) ameliorates colon microvascular dysfunction via endogenous adrenomedullin in Crohn's disease rat model. J Gastroenterol. 2011;46(10): 1187-96.
99. Kono T, Kaneko A, Hira Y, Suzuki T, Chisato N, Ohtake N, et al. Anti-colitis and -adhesion effects of daikenchuto via endogenous adrenomedullin enhancement in Crohn's disease mouse model. J Crohns Colitis. 2010;4(2): 161-70.
100. Akiho H, Nakamura K. Daikenchuto ameliorates muscle hypercontractility in a murine T-cell-mediated persistent gut motor dysfunction model. Digestion. 2011;83(3): 173-9.
101. Inoue K, Naito Y, Takagi T, Hayashi N, Hirai Y, Mizushima K, et al. Daikenchuto, a kampo medicine, regulates intestinal fibrosis associated with decreasing expression of heat shock protein 47 and collagen content in a rat colitis model. Biol Pharm Bull. 2011;34(11): 1659-65.
102. Yasunaga H, Miyata H, Horiguchi H, Kuwabara K, Hashimoto H, Matsuda S. Effect of the Japanese herbal kampo medicine dai-kenchu-to on postoperative adhesive small bowel obstruction requiring long-tube decompression: a propensity score analysis. Evid Based Complement Alternat Med. 2011;2011: 264289. doi:10.1155/2011/264289.
103. Yoshikawa K, Shimada M, Nishioka M, Kurita N, Iwata T, Morimoto S, et al. The effects of the Kampo medicine (Japanese herbal medicine) "Daikenchuto" on the surgical inflammatory response following laparoscopic colorectal resection. Surg Today. 2012;42(7): 646-51.
104. Kase Y, Hayakawa T, Takeda S, Ishige A, Aburada M, Okada M. Pharmacological studies on antidiarrheal effects of Hangeshashin- to. Biol Pharm Bull. 1996;19(10): 1367-70.
105. Kase Y, Hayakawa T, Ishige A, Aburada M, Komatsu Y. The effects of Hange-shashin-to on the content of prostaglandin E2 and water absorption in the large intestine of rats. Biol Pharm Bull. 1997;20(9): 954-7.
106. Kase Y, Saitoh K, Ishige A, Komatsu Y. Mechanisms by which Hange-shashin-to reduces prostaglandin E2 levels. Biol Pharm Bull. 1998;21(12): 1277-81.
107. Kase Y, Saitoh K, Yuzurihara M, Ishige A, Komatsu Y. Effects of Hange-shashin-to on cholera toxin-induced fluid secretion in the small intestine of rats. Biol Pharm Bull. 1998;21(2): 117-20.
108. Kase Y, Saitoh K, Makino B, Hashimoto K, Ishige A, Komatsu Y. Relationship between the antidiarrhoeal effects of Hange- Shashin-To and its active components. Phytother Res. 1999;13(6): 468-73.
109. Naito T, Itoh H, Yasunaga F, Takeyama M. Hange-shashin-to raises levels of somatostatin, motilin, and gastrin in the plasma of healthy subjects. Biol Pharm Bull. 2002;25(3): 327-31.
110. Naito T, Itoh H, Takeyama M. Comparison of the effects of hange-shashin-to and rikkunshi-to on human plasma calcitonin gene-related peptide and substance P levels. Biol Pharm Bull. 2003;26(8): 1104-7.
111. Kawashima K, Nomura A, Makino T, Saito K, Kano Y. Pharmacological properties of traditional medicine (XXIX): effect of Hange-shashin-to and the combinations of its herbal constituents on rat experimental colitis. Biol Pharm Bull. 2004;27(10): 1599-603.
112. Takasuna K, Kasai Y, Kitano Y, Mori K, Kobayashi R, Hagiwara T, et al. Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in Rats. Jpn J Pharmacol. 1995;86(10): 978-84.
113. Takasuna K, Hagiwara T, Watanabe K, Onose S, Yoshida S, Kumazawa E, et al. Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea. Cnacer Chemother Pharmacol. 2006;58: 494-503.
114. Kase Y, Hayakawa T, Aburada M, Komatsu Y, Kamataki T. Preventive effects of Hange-shashin-to on irinotecan hydrochloride- caused diarrhea and its relevance to the colonic prostaglandin E2 and water absorption in the rat. Jpn J Pharmacol. 1997;75(4): 407-13.
115. Mori K, Kondo T, Kamiyama Y, Kano Y, Tominaga K. Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer. Cnacer Chemother Pharmacol. 2003;51: 403-6.
116. Naito T, Itoh H, Yasunaga F, Takeyama M. Rikkunshi-to raises levels of somatostatin and gastrin in human plasma. Biol Pharm Bull. 2001;24(7): 841-3.
117. Naito T, Itoh H, Takeyama M. Some gastrointestinal function regulatory Kampo medicines have modulatory effects on human plasma adrenocorticotropic hormone and cortisol levels with continual stress exposure. Biol Pharm Bull. 2003;26(1): 101-4.
118. Yakabi K, Kurosawa S, Tamai M, Yuzurihara M, Nahata M, Ohno S, et al. Rikkunshito and 5-HT2C receptor antagonist improve cisplatin-induced anorexia via hypothalamic ghrelin interaction. Regul Pept. 2010;161(1-3): 97-105.
119. Sadakane C, Muto S, Nakagawa K, Ohnishi S, Saegusa Y, Nahata M, et al. 10-Gingerol, a component of rikkunshito, improves cisplatin-induced anorexia by inhibiting acylated ghrelin degradation. Biochem Biophys Res Commun. 2011; 412(3): 506-11.
120. Ohno T, Yanai M, Ando H, Toyomasu Y, Ogawa A, Morita H, et al. Rikkunshito, a traditional Japanese medicine, suppresses cisplatin-induced anorexia in humans. Clin Exp Gastroenterol. 2011;4: 291-6.
121. Seike J, Sawada T, Kawakita N, Yamamoto Y, Yuasa Y, Yamai H, et al. A new candidate supporting drug, rikkunshito, for the QOL in advanced esophageal cancer patients with chemotherapy using docetaxel/5-FU/CDDP. Int J Surg Oncol. 2011;2011: 715623.